Magnusson Martin, Molvin John, Engström Gunnar, Svensson-Färbom Patrik, Persson Margaretha, Christensson Anders, Nilsson Peter, Melander Olle
Department of Clinical Sciences, Lund University, Malmö, Sweden.
Department of Cardiology, Skåne University Hospital, Malmö, Sweden.
PLoS One. 2016 May 24;11(5):e0155735. doi: 10.1371/journal.pone.0155735. eCollection 2016.
We recently reported a relationship between plasma levels of cystatin C and incidence of the metabolic syndrome (MetS) among the first 2,369 subjects who participated in the re-examination study of the population-based Malmö and Diet Cancer Cardiovascular cohort (MDC-CC-re-exam). In this study we aimed to replicate these results and also investigate if cystatin C was causally associated with MetS and diabetes.
We estimated the effect size of the strongest GWAS derived cystatin C SNP (major allele of rs13038305) on plasma cystatin C in the now completed MDC-CC-re-exam (n = 3,734) and thereafter examined the association between plasma cystatin C (403 cases of diabetes and 2665 controls) as well as rs13038305 (235 cases and 2425 controls) with incident diabetes. The association of rs13038305 and incident MetS (511 cases of MetS and 1980 controls) was similarly investigated in the whole MDC-CC-re-exam. We also attempted to replicate our previously shown association of cystatin C with incident MetS in subjects from the MDC-CC-re-exam (147 cases and 711 controls) that were not included in our previous report.
In the entire MDC-CC-re-exam, each copy of the major allele of rs13038305 was associated with approximately 0.30 standard deviation (SD) higher plasma concentration of cystatin C (β = 0.33, p = 4.2E-28) in age and sex adjusted analysis. Cystatin C in plasma was not associated with incident diabetes after adjustment for known diabetes risk factors (OR per 1 SD increment 0.99 (0.86-1.13), p = 0.842). In the replication cohort of MDC-CC-re-exam, the OR (95% CI) for incident MetS in subjects belonging to quartiles 1, 2, 3 and 4 of plasma cystatin C levels was 1.00 (reference), 1.21 (0.70-2.07), 1.62 (0.95-2.78) and 1.72 (1.01-2.93) (ptrend = 0.026) in age and sex adjusted analysis. In the entire MDC-CC-re-exam the odds ratio for incident MetS and diabetes per copy of the major rs13038305 allele was 1.13, (0.95-1.34), p = 0.160 and 1.07, 95% CI 0.89-1.30, p = 0.478, respectively.
We were able to replicate our previously shown association between high levels of cystatin C and increased risk of future development of MetS. However, a causal involvement of cystatin C in the etiology of MetS or diabetes seems unlikely since genetic elevation of plasma cystatin C was not significantly related to incidence of these diseases.
我们最近报道了在参加基于人群的马尔默饮食与癌症心血管队列再检查研究(MDC - CC - re - exam)的最初2369名受试者中,血浆胱抑素C水平与代谢综合征(MetS)发病率之间的关系。在本研究中,我们旨在重复这些结果,并调查胱抑素C是否与MetS和糖尿病存在因果关联。
我们在现已完成的MDC - CC - re - exam(n = 3734)中估计了全基因组关联研究(GWAS)得出的最强的胱抑素C单核苷酸多态性(SNP,rs13038305的主要等位基因)对血浆胱抑素C的效应大小,随后检查血浆胱抑素C(403例糖尿病患者和2665例对照)以及rs13038305(235例和2425例对照)与新发糖尿病之间的关联。在整个MDC - CC - re - exam中,同样研究了rs13038305与新发MetS(511例MetS患者和1980例对照)之间的关联。我们还试图在之前报告中未纳入的MDC - CC - re - exam受试者(147例和711例对照)中重复我们之前所显示的胱抑素C与新发MetS之间的关联。
在整个MDC - CC - re - exam中,在年龄和性别校正分析中,rs13038305的主要等位基因的每个拷贝与血浆胱抑素C浓度升高约0.30标准差(SD)相关(β = 0.33,p = 4.2E - 28)。在对已知糖尿病风险因素进行校正后,血浆胱抑素C与新发糖尿病无关(每增加1 SD的比值比为0.99(0.86 - 1.13),p = 0.842)。在MDC - CC - re - exam的重复队列中,在年龄和性别校正分析中,血浆胱抑素C水平处于四分位数1、2、3和4的受试者中,新发MetS的比值比(95%可信区间)分别为1.00(参考值)、1.21(0.70 - 2.07)、1.62(0.95 - 2.78)和1.72(1.01 - 2.93)(趋势p值 = 0.026)。在整个MDC - CC - re - exam中,rs13038305主要等位基因的每个拷贝与新发MetS和糖尿病的比值比分别为1.13(0.95 - 1.34),p = 0.160和1.07,95%可信区间为0.89 - 1.30,p = 0.478。
我们能够重复我们之前所显示的高水平胱抑素C与未来发生MetS风险增加之间的关联。然而,由于血浆胱抑素C的遗传升高与这些疾病的发病率没有显著相关性,因此胱抑素C在MetS或糖尿病病因学中的因果关系似乎不太可能。